Urinary Tract Infection (Klebsiella pneumoniae)

Overview


Plain-Language Overview

Urinary Tract Infection (Klebsiella pneumoniae) is an infection that affects the urinary system, which includes the kidneys, bladder, and urethra. This condition occurs when the bacteria Klebsiella pneumoniae enter and multiply in the urinary tract, causing symptoms like painful urination, frequent urge to urinate, and lower abdominal discomfort. The infection can lead to inflammation and sometimes spread to the kidneys, causing more severe illness. It mainly affects the bladder but can involve other parts of the urinary tract. If untreated, it may cause complications such as kidney damage or bloodstream infection. The urinary system’s main function of removing waste and excess fluids from the body is disrupted during infection.

Clinical Definition

Urinary Tract Infection (Klebsiella pneumoniae) is a bacterial infection characterized by the colonization and invasion of the urinary tract by the gram-negative bacillus Klebsiella pneumoniae. This pathogen is a common cause of nosocomial and community-acquired UTIs, especially in patients with urinary catheters or structural abnormalities. The infection results from bacterial adherence to the uroepithelium, leading to inflammation, epithelial damage, and clinical symptoms such as dysuria, urgency, and suprapubic pain. It can involve the lower urinary tract (cystitis) or ascend to the upper tract causing pyelonephritis. The presence of a polysaccharide capsule in Klebsiella pneumoniae enhances its virulence by resisting phagocytosis. This infection is clinically significant due to its potential for antibiotic resistance and complications like sepsis.

Inciting Event

  • Introduction of bacteria into the urinary tract via ascending route from the perineum.

  • Urinary catheter placement providing a direct conduit for bacterial entry.

  • Urinary tract obstruction causing urine stasis and bacterial proliferation.

  • Recent antibiotic therapy disrupting normal flora and allowing overgrowth of resistant strains.

Latency Period

  • Hours to days from bacterial colonization to symptom onset in uncomplicated infections.

  • Longer latency in catheter-associated infections due to biofilm development.

  • Rapid symptom progression in patients with impaired immunity or obstruction.

Diagnostic Delay

  • Atypical presentation in elderly or immunocompromised patients leading to missed diagnosis.

  • Misattribution of symptoms to other causes such as vaginitis or prostatitis.

  • Delayed urine culture results causing postponement of targeted therapy.

  • Empiric treatment without culture leading to persistence of resistant organisms.

Clinical Presentation


Signs & Symptoms

  • Dysuria, urinary frequency, and urgency as hallmark lower urinary tract symptoms.

  • Suprapubic pain and discomfort during urination.

  • Fever and chills in upper urinary tract involvement or systemic infection.

  • Cloudy or foul-smelling urine due to bacterial infection.

  • Hematuria may be present in severe mucosal inflammation.

History of Present Illness

  • Dysuria, frequency, and urgency developing over hours to days.

  • Suprapubic pain and hematuria may be present in lower tract infection.

  • Fever and flank pain suggest progression to pyelonephritis.

  • Cloudy or foul-smelling urine indicating bacterial infection.

  • Symptoms often worsen rapidly in complicated or catheter-associated infections.

Past Medical History

  • Previous urinary tract infections increase risk of recurrence with resistant organisms.

  • History of urinary tract instrumentation such as catheterization or cystoscopy.

  • Diabetes mellitus impairing host defenses and glycosuria promoting bacterial growth.

  • Known urinary tract abnormalities including stones or strictures.

  • Recent hospitalization or antibiotic use selecting for multidrug-resistant strains.

Family History

  • No significant heritable predisposition to urinary tract infection with Klebsiella pneumoniae.

  • Rare familial syndromes causing urinary tract malformations may increase infection risk.

  • No direct association with genetic immune deficiencies specifically predisposing to this infection.

Physical Exam Findings

  • Suprapubic tenderness on palpation indicating bladder inflammation.

  • Costovertebral angle (CVA) tenderness suggesting pyelonephritis.

  • Fever and signs of systemic infection in severe cases.

  • Tachycardia and hypotension in complicated or septic UTI.

Diagnostic Workup


Diagnostic Criteria

Diagnosis is established by urinalysis showing pyuria and bacteriuria, and a urine culture confirming growth of Klebsiella pneumoniae at ≥10^5 colony-forming units/mL. Clinical symptoms such as dysuria, frequency, and urgency support the diagnosis. Imaging may be used if upper tract involvement or complications are suspected. Blood cultures may be indicated in severe cases to detect bacteremia.

Pathophysiology


Key Mechanisms

  • Colonization of the urinary tract by Klebsiella pneumoniae, a gram-negative encapsulated rod with a thick polysaccharide capsule that enhances virulence.

  • Adherence to uroepithelial cells via fimbriae facilitating bacterial persistence and invasion.

  • Biofilm formation on urinary catheters or damaged mucosa promoting chronic infection and antibiotic resistance.

  • Endotoxin release (lipopolysaccharide) triggering local inflammation and systemic symptoms.

  • Immune evasion through capsule-mediated resistance to phagocytosis and complement-mediated killing.

InvolvementDetails
Organs

Bladder is the main organ affected in lower urinary tract infection, presenting with symptoms like dysuria and urgency.

Kidneys may be involved in upper urinary tract infection (pyelonephritis), leading to flank pain and systemic symptoms.

Tissues

Uroepithelium is the specialized tissue lining the urinary tract that is the primary site of bacterial adherence and invasion in infection.

Cells

Neutrophils are the primary immune cells that infiltrate the urinary tract to phagocytose and kill Klebsiella pneumoniae.

Urothelial cells line the urinary tract and act as a physical barrier and participate in immune signaling during infection.

Chemical Mediators

Interleukin-8 (IL-8) is released by infected urothelial cells to recruit neutrophils to the site of infection.

Tumor necrosis factor-alpha (TNF-α) promotes inflammation and helps coordinate the immune response against the bacteria.

Treatments


Pharmacological Treatments

  • Third-generation cephalosporins (e.g., ceftriaxone)

    • Mechanism:
      • Inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins

    • Side effects:
      • Allergic reactions

      • Diarrhea

      • Elevated liver enzymes

    • Clinical role:
      • First-line

  • Fluoroquinolones (e.g., ciprofloxacin)

    • Mechanism:
      • Inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication

    • Side effects:
      • Tendonitis

      • QT prolongation

      • Gastrointestinal upset

    • Clinical role:
      • Second-line

  • Carbapenems (e.g., imipenem)

    • Mechanism:
      • Broad-spectrum beta-lactam antibiotics that inhibit bacterial cell wall synthesis

    • Side effects:
      • Seizures

      • Allergic reactions

      • Gastrointestinal upset

    • Clinical role:
      • Rescue

  • Aminoglycosides (e.g., gentamicin)

    • Mechanism:
      • Inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit

    • Side effects:
      • Nephrotoxicity

      • Ototoxicity

      • Neuromuscular blockade

    • Clinical role:
      • Adjunctive

Non-pharmacological Treatments

  • Ensure adequate hydration to promote urinary flow and bacterial clearance.

  • Implement proper perineal hygiene to reduce bacterial colonization.

  • Use urinary catheterization only when necessary to minimize infection risk.

Prevention


Pharmacological Prevention

  • Low-dose prophylactic antibiotics such as nitrofurantoin in recurrent UTI cases.

  • Cranberry extract supplements may reduce bacterial adherence but evidence is limited.

Non-pharmacological Prevention

  • Adequate hydration to promote regular urine flow and bacterial clearance.

  • Proper perineal hygiene to reduce bacterial colonization near the urethra.

  • Avoidance of unnecessary catheterization to prevent nosocomial infections.

  • Prompt treatment of urinary obstruction to prevent stasis and infection.

Outcome & Complications


Complications

  • Pyelonephritis from ascending infection causing renal parenchymal inflammation.

  • Renal abscess formation due to localized infection.

  • Sepsis and septic shock from systemic spread of Klebsiella pneumoniae.

  • Emphysematous cystitis or pyelonephritis characterized by gas formation in tissues.

Short-term Sequelae Long-term Sequelae
  • Acute kidney injury secondary to severe infection or obstruction.

  • Bacteremia leading to systemic inflammatory response.

  • Urinary retention due to inflammation and edema.

  • Chronic kidney disease from recurrent or severe pyelonephritis.

  • Renal scarring causing long-term functional impairment.

  • Recurrent urinary tract infections due to persistent colonization or anatomical abnormalities.

Differential Diagnoses


Urinary Tract Infection (Klebsiella pneumoniae) versus Urinary Tract Infection (Escherichia coli)

Urinary Tract Infection (Klebsiella pneumoniae)

Urinary Tract Infection (Escherichia coli)

Klebsiella pneumoniae is a common cause of complicated or nosocomial UTI

Escherichia coli is the most common cause of community-acquired UTI

Often associated with prior catheterization or hospitalization

Community-acquired infection without prior instrumentation

Lactose-fermenting, indole-negative on culture

Lactose-fermenting, indole-positive on culture

Urinary Tract Infection (Klebsiella pneumoniae) versus Urinary Tract Infection (Proteus mirabilis)

Urinary Tract Infection (Klebsiella pneumoniae)

Urinary Tract Infection (Proteus mirabilis)

Klebsiella pneumoniae does not typically produce urease

Proteus mirabilis produces urease leading to alkaline urine

No struvite stones typically associated

Struvite stones visible on imaging due to urease activity

Non-motile colonies on culture

Swarming motility on culture plates

Urinary Tract Infection (Klebsiella pneumoniae) versus Acute Pyelonephritis

Urinary Tract Infection (Klebsiella pneumoniae)

Acute Pyelonephritis

Lower urinary tract symptoms without systemic signs

Fever, flank pain, and systemic symptoms predominate

Imaging typically normal or shows bladder involvement only

Renal ultrasound or CT shows renal enlargement or abscess

Pyuria without white blood cell casts

Pyuria with white blood cell casts in urine

Urinary Tract Infection (Klebsiella pneumoniae) versus Cystitis caused by Enterococcus faecalis

Urinary Tract Infection (Klebsiella pneumoniae)

Cystitis caused by Enterococcus faecalis

Gram-negative bacilli, often sensitive to cephalosporins

Gram-positive cocci in chains, often resistant to cephalosporins

Often community-acquired or associated with catheter use

Common in patients with recent antibiotic use or urinary instrumentation

Often treated successfully with cephalosporins or fluoroquinolones

Requires ampicillin or vancomycin due to resistance

Urinary Tract Infection (Klebsiella pneumoniae) versus Fungal Urinary Tract Infection (Candida species)

Urinary Tract Infection (Klebsiella pneumoniae)

Fungal Urinary Tract Infection (Candida species)

Gram-negative rods seen on urine microscopy

Yeast cells or pseudohyphae seen on urine microscopy

Occurs in broader population including healthy individuals

Common in immunocompromised or diabetic patients with indwelling catheters

Treated with antibiotics targeting gram-negative bacteria

Requires antifungal therapy such as fluconazole

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.